Valuation: Exelixis, Inc.

Capitalization 1.19TCr 1.03TCr 961.63Cr 896.31Cr 1.66TCr 1,07500Cr 1.8TCr 11TCr 4.34TCr 51TCr 4.48TCr 4.39TCr 1,85600Cr P/E ratio 2025 *
17.4x
P/E ratio 2026 * 14.6x
Enterprise value 1.14TCr 976.7Cr 914.96Cr 852.81Cr 1.58TCr 1,02300Cr 1.71TCr 11TCr 4.13TCr 48TCr 4.26TCr 4.17TCr 1,76600Cr EV / Sales 2025 *
4.86x
EV / Sales 2026 * 4.15x
Free-Float
98.21%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.02%
1 week+0.43%
Current month+0.43%
1 month+9.88%
3 months+17.11%
6 months+4.70%
Current year+33.21%
More quotes
1 week 43
Extreme 43
44.79
1 month 39.83
Extreme 39.83
44.91
Current year 31.9
Extreme 31.9
49.62
1 year 31.9
Extreme 31.9
49.62
3 years 15.32
Extreme 15.32
49.62
5 years 14.87
Extreme 14.87
49.62
10 years 3.55
Extreme 3.55
49.62
More quotes
Manager TitleAgeSince
Chief Executive Officer 64 22/07/2010
Director of Finance/CFO 57 15/07/2015
Chief Operating Officer 62 01/02/2016
Director TitleAgeSince
Director/Board Member 68 01/02/2004
Director/Board Member 81 01/08/2004
Chairman 76 01/01/1998
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.02%+0.43%+23.09%+157.61% 1.19TCr
-2.68%-1.46%+30.24%+105.16% 5.49TCr
-0.51%-1.81%+170.81%+925.64% 4.35TCr
+0.90%-0.87%+75.84%+15.31% 3.81TCr
+0.26%-6.69%-19.01%-42.27% 2.31TCr
-1.45%-0.34%+30.97%-37.78% 1.95TCr
-0.97%+4.69%+98.42%-40.74% 1.73TCr
+0.57%+0.98%+89.61%+302.27% 1.47TCr
-2.66%+2.35%+4.51%+2,232.48% 1.41TCr
+2.45%+0.79%+147.98% - 1.38TCr
Average -0.41%-0.31%+65.24%+401.96% 2.51TCr
Weighted average by Cap. -0.68%-1.01%+69.89%+345.98%
See all sector performances

Financials

2025 *2026 *
Net sales 233.57Cr 200.78Cr 188.09Cr 175.31Cr 323.81Cr 21TCr 352.21Cr 2.2TCr 849.46Cr 9.93TCr 876.65Cr 857.94Cr 36TCr 261.25Cr 224.57Cr 210.38Cr 196.09Cr 362.18Cr 24TCr 393.94Cr 2.46TCr 950.12Cr 11TCr 980.53Cr 959.61Cr 41TCr
Net income 72Cr 62Cr 58Cr 54Cr 99Cr 6.44TCr 107.98Cr 674.46Cr 260.42Cr 3.04TCr 268.75Cr 263.02Cr 11TCr 80Cr 69Cr 65Cr 60Cr 111.07Cr 7.21TCr 120.81Cr 754.62Cr 291.37Cr 3.41TCr 300.7Cr 294.28Cr 12TCr
Net Debt -58Cr -50Cr -47Cr -43Cr -80Cr -5.22TCr -87Cr -545.85Cr -210.76Cr -2.46TCr -217.51Cr -212.87Cr -9.01TCr -110.45Cr -95Cr -89Cr -83Cr -153.12Cr -9.94TCr -166.55Cr -1.04TCr -401.68Cr -4.69TCr -414.54Cr -405.69Cr -17TCr
More financial data * Estimated data
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Employees
1,147
Calendar
More about the company
Date Price Change Volume
05/25/05 44.36 $ -0.02% 21,93,734
04/25/04 44.37 $ +0.82% 20,55,158
03/25/03 44.01 $ +1.31% 27,29,381
02/25/02 43.44 $ +0.02% 22,44,956
01/25/01 43.43 $ -1.68% 24,77,601

Delayed Quote Nasdaq, December 06, 2025 at 02:30 am IST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
BB
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
44.36USD
Average target price
44.94USD
Spread / Average Target
+1.32%
Consensus

Quarterly revenue - Rate of surprise